Welcome to our dedicated page for Fennec Pharmaceuticals SEC filings (Ticker: FENC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Fennec Pharmaceuticals Inc. filings document formal disclosures for its commercial specialty pharmaceutical business, PEDMARK® product updates, and Nasdaq-listed common shares. Recent Form 8-K reports cover financial results, scientific presentations and investigator-sponsored studies involving sodium thiosulfate injection, and a license agreement resolving litigation tied to a proposed generic version of PEDMARK.
The company’s proxy materials cover director elections, board composition, executive compensation, equity awards, and shareholder voting matters. Other current reports disclose governance changes, registered common shares with no par value, and exhibits furnished with press releases concerning business, clinical, and product-related developments.
Fennec Pharmaceuticals Chief Strategy Officer Christiana Marie Cioffi acquired additional common shares through a derivative exercise/conversion. On April 30, 2026, 155 common shares were released from restriction from shares awarded on March 28, 2025, increasing her directly held stake.
Following this release, Cioffi directly owns 24,020 common shares. The transaction reflects routine equity-based compensation vesting rather than an open-market purchase, as the reported price per share was $0.0000.
FENNEC PHARMACEUTICALS INC. Chief Executive Officer Jeffrey S. Hackman reported acquiring 1,159 common shares through the exercise or conversion of a derivative award. A footnote explains these shares were released from restriction from shares awarded on 3/28/2025.
After this transaction, Hackman directly holds 61,666 common shares. The filing reflects a routine compensation-related release of previously granted equity rather than an open-market purchase or sale.
FENNEC PHARMACEUTICALS INC. Chief Financial Officer Robert Andrade acquired 1,703 common shares on April 30, 2026 through an exercise or conversion of a derivative security reported at $0.00 per share.
After this transaction, Andrade directly owns 287,566 common shares. A footnote explains these shares were released from restriction from awards originally granted on May 16, 2024 and March 28, 2025.
FENNEC PHARMACEUTICALS INC. Chief Medical Officer Pierre Sargis Sayad acquired 168 Common Shares on April 30, 2026 through the release of restricted shares that were originally awarded on March 28, 2025. After this compensation-related share release, he directly owns a total of 20,847 Common Shares.
Fennec Pharmaceuticals Inc. reported a planned change to its Board of Directors. On April 27, 2026, director Rostislav Raykov notified the company that he plans to retire from the Board and will not stand for re-election at the 2026 annual meeting of shareholders.
His current term will end immediately after the annual meeting, and his departure is stated to be not due to any disagreement with the company’s operations, policies, or practices. Before the meeting, the Board decided to reduce its size from six to five directors, effective immediately following the annual meeting, and the company expects no Board vacancies after the change.
FENNEC PHARMACEUTICALS INC. ownership update: 1,981,501 common shares (CUSIP 31447P100) are reported as beneficially owned, representing 5.7% of the class. The disclosure is a joint filing by AIGH Capital Management LLC, AIGH Investment Partners LLC and Orin Hirschman and shows sole voting and dispositive power over these shares.
The filing lists the filers' principal business address and states the signature date as 04/28/2026. This is a routine Schedule 13G ownership disclosure under Rule 13d-1.
Fennec Pharmaceuticals Inc. is holding a virtual annual and special shareholder meeting on June 10, 2026 to vote on key governance and compensation items. Shareholders of record at 5:00 p.m. EDT on April 13, 2026, each holding one vote per common share, may participate online.
Shareholders will elect five directors, appoint Haskell & White LLP as auditors, and cast advisory votes on executive compensation and on how often that say‑on‑pay vote should occur, with the board recommending every year. As of April 13, 2026, there were 34,712,756 common shares outstanding.
Special business includes increasing the share reserve under Fennec’s 2020 Equity Incentive Plan to 10,000,000 common shares, which the circular states equals about 28.81% of shares outstanding, and approving a separate 2026 Equity Inducement Plan covering up to 600,000 shares, primarily for newly hired employees. The proxy also details executive and director pay, outstanding options, and severance and change‑of‑control provisions for senior management.
Fennec Pharmaceuticals Inc. reported that four scientific abstracts involving its ototoxicity drug PEDMARK (sodium thiosulfate injection) have been accepted for presentation or publication at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Two studies will be presented as posters, including a Japanese pediatric trial on delayed sodium thiosulfate and a randomized Phase 1 trial in men with metastatic germ cell tumors. Two additional PEDMARK-focused studies will appear as abstract-only publications, covering real-world feasibility in young adults and audiometric outcomes in adults with head and neck cancer. The company highlights PEDMARK as the first FDA-approved therapy to reduce cisplatin-related hearing loss in eligible pediatric patients, noting its clinical evidence from two Phase 3 trials and international approvals under the PEDMARQSI brand.
Fennec Pharmaceuticals Inc. reported that the University of Arizona Cancer Center has initiated an investigator-sponsored study evaluating PEDMARK® (sodium thiosulfate injection) in adolescent, young adult, and adult patients with head and neck and testicular cancers receiving cisplatin.
The company explains that cisplatin-based chemotherapy is widely used but can cause permanent hearing loss in a significant share of patients, and PEDMARK is already approved to reduce ototoxicity risk in pediatric patients with localized, non-metastatic solid tumors. The new independent, institution-led study is intended to further build real-world evidence for PEDMARK in broader cancer populations beyond those in the pivotal pediatric trials.
Cioffi Christiana Marie reported acquisition or exercise transactions in this Form 4 filing.
FENNEC PHARMACEUTICALS INC. Chief Strategy Officer Christiana Marie Cioffi reported compensation-related equity awards. She received incentive stock options for 120,000 common shares at $5.77 per share, expiring on March 31, 2036, under the 2020 Equity Incentive Plan. Performance share units and previously awarded restricted shares also vested, increasing her directly held common shares to 23,865 as of March 28, 2026.